Addressing Unmet Needs for Cholangiocarcinoma & Myeloid Lymphoid Neoplasms
ASCO® 2023 Insights: "IMbrave050 Data on Atezolizumab + Bevacizumab vs. Active Surveillance in HCC"
By
ecancer
FEATURING
Masatoshi Kudo
By
ecancer
FEATURING
Masatoshi Kudo
Login to view comments.
Click here to Login